The localization of PSMA expression in the neovasculature of RAIR-DTC instead of tumor cells as in PCa could potentially explain the relatively poor outcomes with [177Lu]Lu-PSMA-617 therapy in DTC compared to PCa. The gene discussed is FOLH1; the disease is neoplasm.